Abbott Laboratories (NYSE:ABT) Shares Acquired by Tradewinds Capital Management LLC

Tradewinds Capital Management LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 441.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,625 shares of the healthcare product maker’s stock after acquiring an additional 2,140 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Abbott Laboratories were worth $298,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in ABT. Schonfeld Strategic Advisors LLC raised its stake in Abbott Laboratories by 1,121.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 48,663 shares of the healthcare product maker’s stock valued at $4,713,000 after acquiring an additional 44,679 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of Abbott Laboratories by 2.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 181,959 shares of the healthcare product maker’s stock worth $17,623,000 after buying an additional 4,200 shares in the last quarter. AXQ Capital LP purchased a new position in Abbott Laboratories in the 3rd quarter valued at approximately $484,000. Alerus Financial NA increased its stake in Abbott Laboratories by 2,457.1% in the 3rd quarter. Alerus Financial NA now owns 117,754 shares of the healthcare product maker’s stock valued at $11,405,000 after purchasing an additional 113,149 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Abbott Laboratories by 6.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,403,264 shares of the healthcare product maker’s stock valued at $135,906,000 after purchasing an additional 82,846 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Jr. Robert E. Funck sold 10,097 shares of Abbott Laboratories stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $104.57, for a total value of $1,055,843.29. Following the completion of the transaction, the executive vice president now directly owns 211,341 shares in the company, valued at $22,099,928.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Lisa D. Earnhardt sold 22,852 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $106.25, for a total value of $2,428,025.00. Following the completion of the transaction, the executive vice president now directly owns 61,462 shares of the company’s stock, valued at approximately $6,530,337.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jr. Robert E. Funck sold 10,097 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $104.57, for a total value of $1,055,843.29. Following the completion of the transaction, the executive vice president now directly owns 211,341 shares of the company’s stock, valued at $22,099,928.37. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ABT shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Citigroup lowered their target price on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a report on Wednesday, May 22nd. Evercore ISI lowered their target price on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating on the stock in a report on Tuesday. Barclays decreased their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a report on Monday, April 22nd. Finally, The Goldman Sachs Group started coverage on Abbott Laboratories in a report on Thursday, May 30th. They set a “buy” rating and a $121.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $120.18.

Abbott Laboratories Stock Down 0.8 %

Shares of NYSE ABT traded down $0.87 during midday trading on Wednesday, reaching $102.33. 953,900 shares of the company’s stock were exchanged, compared to its average volume of 5,645,135. The stock has a market capitalization of $178.02 billion, a PE ratio of 31.99, a price-to-earnings-growth ratio of 2.50 and a beta of 0.72. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64. The business’s fifty day moving average price is $104.63 and its two-hundred day moving average price is $110.05. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.11 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. The business had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 earnings per share. Analysts forecast that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, July 15th. This represents a $2.20 dividend on an annualized basis and a yield of 2.15%. Abbott Laboratories’s dividend payout ratio (DPR) is 68.54%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.